Tycoon Group Holdings Limited Overview
Tycoon Group is a Hong Kong-based, founder-controlled omnichannel brand marketing and distribution integrator for proprietary Chinese medicines (PCM), health supplements, skincare and personal care products. It sits between brand owners and retailers, providing brand agency, marketing, promotion, logistics and sell-in to chain retailers, pharmacies and traders, and supplements this with a Hong Kong PCM retail chain (Hong Ning Hong, 70%-owned) and a Mainland China cross-border e-commerce operation (Combo Win Asia group, reconsolidated in March 2025). The group reports coverage of nearly 100,000 online and offline points of sale across Hong Kong, Macau, Mainland China and Southeast Asia, representing over 300 brands and more than 2,000 SKUs, and owns more than 60 registered trademarks for self-owned brands such as Boost & Guard Pro and Craft by Wakan [S1]. It is a micro-cap (~HK$219M) with thin margins (FY2025 net margin 1.4%), elevated short-term leverage, a highly concentrated customer base and a strategic minority shareholder, Jacobson Pharma (17.04%) [S1].
Company's own description (FY2025 annual results, paraphrased)
The company describes itself as a Hong Kong-based omnichannel marketing and management service integrator of healthcare and wellbeing products, offering one-stop brand agency, promotion and marketing, management, distribution and sales services for PCM, health supplements, skincare, personal care and other healthcare products. It claims a network of nearly 100,000 online and offline sales points across Hong Kong, Macau, the PRC and Southeast Asia, more than 300 represented brands and a portfolio of over 2,000 products, and characterises itself as a diversified industry pioneer with a leading market position in Hong Kong [S1]. The company also states it is one of the major PCM distributors in Hong Kong and has established relationships with the top two personal care chain retailers in Hong Kong [S5][S6].
Business model and revenue model
| Channel / segment | Model | FY2025 external revenue (HKD Mn) | Share |
|---|---|---|---|
| Distribution | Wholesale sell-in of agency, collaborative and own-brand products to chain retailers, non-chain retailers (mainly pharmacies) and traders in HK, Macau, Mainland China and Southeast Asia | 701.6 | 64.0% |
| E-commerce | Cross-border e-commerce wholesale and online flagship stores plus domestic offline distribution in Mainland China (Combo Win Asia group) | 243.4 | 22.2% |
| Retail store | Brick-and-mortar PCM / proprietary medicine retail through Hong Ning Hong Limited (70%) | 151.7 | 13.8% |
All revenue is recognised as sale of goods at a point in time (FY2025: HK$1,096.6M, 100%) [S1]. There is no disclosed subscription, licensing or service-fee revenue line; the "omnichannel brand marketing and management services" are monetised through product margin rather than separately invoiced fees. The revenue model is therefore effectively 100% product resale, with three channels:
Source: [S1] segment note.
Value-chain position
Tycoon occupies the mid-stream "market expansion services" layer: it does not manufacture (product sourcing via procurement centres in Japan, South Korea, Singapore, Malaysia, Thailand, Vietnam, Indonesia, Cambodia, Macau, Australia and France) [S1], but owns brand IP for self-owned lines, holds exclusive territorial agency rights for third-party brands, and controls a small downstream retail footprint. Margin capture improves with own-brand mix; agency/distribution volumes depend on brand-owner contracts and retailer access.
Customer types and end-markets
Chain retailers: the largest single customer ("Customer A", distribution segment) contributed HK$457.6M in FY2025 (41.7% of group revenue) and HK$471.8M in FY2024 (53.9%) [S1][S3]. The company does not name it; given its stated relationships with Hong Kong's top two personal care chains, it is likely one of those chains (unconfirmed).
Non-chain retailers: (independent pharmacies) and traders.
Consumers: via HNH retail stores and Mainland online flagship stores.
End-markets: Hong Kong local consumers and Mainland Individual Visit Scheme (IVS) tourists; Macau; Mainland China cross-border e-commerce shoppers; Chinese-diaspora and local consumers in Singapore, Malaysia and Thailand [S1][S2].
Independent characterisation
Tycoon is best understood as a leveraged, working-capital-intensive consumer-health distributor whose reported growth has been dominated by consolidation accounting (the 2023 deconsolidation and 2025 reconsolidation of its Mainland e-commerce arm) rather than organic expansion. Its underlying Hong Kong distribution franchise has been flat (HK$533.0M in FY2024 to HK$524.2M in FY2025) [S1]; Southeast Asia has grown from a low base but was deliberately cut back in 1H2026 to improve margin [S2]. Gross margin (24–27%) sits well below brand-owning peers such as JBM Healthcare (55.8%) [S14], reflecting a distribution-heavy mix. The equity story rests on own-brand margin expansion, Southeast Asian penetration and synergies with Jacobson Pharma, against persistent risks from customer concentration, refinancing of short-dated bank debt and a controlling-shareholder pledge history.
Strategy
Stated strategic themes (FY2025 annual results and 1H2026 interim)
Management's outlook heading for both periods is "Empowering the Growth, Embracing the NEW" [S1][S2]. Paraphrased pillars:
-
Southeast Asian regional coverage — consolidate share in Singapore, Malaysia and Thailand; deploy sales in Vietnam, Indonesia and Cambodia; target comprehensive SEA coverage [S1][S2].
-
Margin over volume in SEA — 1H2026 pivot away from low-margin SKUs toward higher-margin products [S2].
-
Own and collaborative brands — invest in higher-margin own brands across categories for SEA, local and Mainland travellers; >60 trademarks [S1].
-
Shareholder synergies with Jacobson — use Jacobson's pharmaceutical regulatory network to accelerate market-entry qualifications in Vietnam, Indonesia and Cambodia [S1][S2].
-
Cost discipline — "stringent" cost control, reduced administrative expenses and finance costs [S2].
-
Mainland e-commerce optimisation — product-mix optimisation, more international-brand online flagship stores, market-driven bestsellers amid consumption downgrading [S2].
Initiatives announced in the last 24 months
| Initiative | Date | Detail | Source |
|---|---|---|---|
| CWA reconsolidation | Feb–Mar 2025 | Put-option repurchase of 51% CWA; e-commerce segment restored | [S1] |
| Jacobson strategic subscription | Apr–May 2025 | 94M shares at HK$0.50; HK$46.7M net for inventory (26.0), logistics (12.0), marketing (5.0), working capital (3.7) — fully used by Dec 2025 | [S1] |
| Sido Muncul partnership | FY2025 | Exclusive Malaysian F&B-channel agency for Kuku Bima Ener-G! | [S1] |
| Po Chai Pills Singapore exclusivity | FY2025 | Exclusive agency via major chain retail in Singapore; extended to Cambodia by 1H2026 | [S1][S2] |
| HNH Mong Kok store | FY2025 | New retail outlet in tourist hotspot | [S1] |
| Po Wo Tong concept store | End-2025 | Harbour City pop-up; celebrity endorsement (Selena Lee) | [S1] |
| New century-old collaborative brand | FY2025 | Name not disclosed | [S1] |
| Unichi exclusive agency (HK) | 1H2026 | Hair-growth gummies | [S2] |
| SEA product-mix restructuring | 1H2026 | Deliberate reduction of low-margin lines | [S2] |
| Auditor change for cost-effectiveness | Nov 2025 | PwC → Crowe | [S8] |
| Disposal of a subsidiary | 1H2026 | Gain HK$4.3M; identity not disclosed | [S2] |
Medium-term targets / guidance
No quantitative medium-term financial targets are publicly disclosed. Qualitative guidance: 2H2026 revenue expected to improve on seasonal peak and cost control, with the group aiming to stay profitable [S2][S6]; Thailand higher-margin sales expected to grow healthily in 2026 [S2].
Products & Services
Pricing models for individual SKUs are not publicly disclosed; all products are sold on a wholesale-price (distribution) or retail-price (HNH, online flagship) basis. Launch years are given only where disclosed.
Self-owned brands (higher-margin; >60 registered trademarks) [S1][S2][S3]
| Brand | Product | Description / positioning | Status / notes |
|---|---|---|---|
| Boost & Guard Pro (BG Pro 博健專研) | BG Pro Immunoglobulin Capsules | Immune-support supplement | Best-seller FY2024–FY2025 |
| BG Pro | BG Pro Ultra Purity Deep Sea Fish Oil | Omega-3 supplement | Best-seller FY2024–1H2026 |
| BG Pro | BG Pro Dr. Growth Calcium | Children's growth calcium | Best-seller 1H2026 |
| BG Pro | BG Pro CoQ-10 (medical-grade) | Cardiovascular / energy supplement | Upgraded/improved line |
| BG Pro | BG Pro Brain Booster | Cognitive supplement | Launched FY2024 |
| Craft by Wakan (和漢匠心) | Craft by Wakan Japanese Probiotics | Multi-strain probiotic (Japan-sourced) | Best-seller FY2024–1H2026; previously endorsed by Ms. Lin Min Chen |
| Craft by Wakan | Japan Liver Boost EX | Liver-support supplement | Upgraded line |
| Craft by Wakan | Japan Joint Active | Joint-health supplement | Upgraded line |
| Craft by Wakan | Japan SlimPro | Slimming formula | Launched FY2024 |
| Legacy predecessors | "Boost & Guard (BG 博健科研)", "Wakan (和漢)", "Kinmen (金門)" | Own brands named in FY2022 | Evolved into current lines [S4] |
Collaborative brands [S1][S2]
| Brand | Products | Notes |
|---|---|---|
| Kinmen Qiangxiao (金門強效) | I-Tiao-Gung Plaster (essential-oil patch); I-Tiao-Gung Pain Relief Penetrating Liquid; I-Tiao-Gung Pain Relief Roller Cream | Topical pain relief; ambassador Mr. Louis Cheung; liquid and roller cream launched FY2024 |
| SEASONS (田心日辰) | SEASONS NMN 40000 | Anti-ageing NMN supplement; ambassador Ms. Christine Kuo |
| MiTime | MiTime Multivitamin; MiTime Kids DHA 60 Softgels (fish/algal oil) | Family / children's nutrition |
| Po Wo Tong (寶和堂) | Dampness Removing Pills; Dampness Removing Bath Capsule | Century-old HK brand acquired personally by the chairman and co-developed with the group; ambassador Ms. Selena Lee; Harbour City pop-up concept store since end-2025 |
| Unnamed century-old brand | — | A new century-old collaborative brand added during FY2025 [S1] |
Agency / third-party brands (selected, as disclosed) [S1][S2][S3][S4]
| Brand (owner) | Category | Rights / territory |
|---|---|---|
| Li Chung Shing Tong Po Chai Pills 李眾勝堂保濟丸 (JBM Group) | PCM (digestive) | Represented in HK; exclusive agency in Singapore (major chain retail, from FY2025) and Cambodia (from 1H2026) |
| Ho Chai Kung 何濟公 (JBM Group) | PCM | Represented |
| Flying Eagle Medicated Oil 飛鷹活絡油 (Europharm / JBM Group) | Topical PCM | Represented; exclusive in Singapore for Europharm Singapore products |
| Tin Hee Tong 天喜堂 incl. Tin Hee Pills (JBM Group) | PCM | Represented |
| Kuku Bima Ener-G! (Sido Muncul, Indonesia) | Energy-drink powder | Exclusive agency, food & beverage channel, Malaysia (from FY2025) |
| Unichi | Bear-shaped hair-growth gummies | Exclusive agency, Hong Kong (disclosed 1H2026) |
| Kaminowa (Japan) | Hair-loss prevention/care | Exclusive agency HK, Macau, Singapore |
| Helaslim (Japan) | Slimming / beauty | Exclusive agency, Singapore |
| PNKids (Singapore) | Children's multivitamins | Exclusive, Singapore and Malaysia (obtained FY2024) |
| plu (Korea) | Body care | Distribution rights HK, Macau, Singapore, Malaysia (FY2024) |
| Dong-E-E-Jiao 東阿阿膠 (Mainland) | Donkey-hide gelatin tonic | General distributor in Hong Kong (from FY2024) |
| Taiji Huoxiang Zhengqi Oral Liquid 太極牌藿香正氣口服液 | PCM oral liquid | Represented in Hong Kong (FY2024) |
| TJ-TYT (Toong Yin Thong) — Watermelon Frost Complex Powder, Pil Tu Tong, Vegetarian Bai Feng Wan | PCM | Distribution rights in Malaysia since 2022 |
| Double Panda 雙熊貓牌 — Qian Li Zhui Feng You, De-Kof cough syrup, American Ginseng Capsules | PCM / tonic | Singapore and Malaysia |
| Culturelle® | Probiotics | Sole distributor in China (FY2022); exclusive HK & Macau (FY2024) — current status not reconfirmed in FY2025 disclosures |
| Biolane (France) | Baby wash care | Exclusive HK, Singapore, Malaysia (FY2022–FY2024) — not reconfirmed in FY2025 |
| Dr Banggiwon (Korea) | Anti-hair-loss | Exclusive HK (FY2022) — not reconfirmed later |
| Nu-Prep (Biotropics Malaysia) | Herbal health | Exclusive HK & Macau (FY2022) — not reconfirmed later |
Services
Omnichannel brand marketing & management: brand agency, promotion (TV, outdoor, Xiaohongshu social campaigns, celebrity ambassadors), management, distribution and sales; monetised via product margin, no separate fee disclosure [S1].
Co-development with retailers: active collaboration with two major Hong Kong personal-care chains to launch tailored products [S1].
Retail (HNH): retail and wholesale of pharmaceutical products and proprietary medicines; stores include a new Mong Kok outlet (FY2025); exact store count not publicly disclosed (one outlet at the May 2023 acquisition) [S1][S3].
Financial Narrative
All figures audited, HK$M, fiscal years ended 31 December. Sources: [S4] (FY2021–FY2022), [S3] (FY2023–FY2024), [S1] (FY2025); cash flow and some ratios from S&P Global via StockAnalysis [S7]; derived figures marked.
Income statement
FY2023 includes non-recurring gains of HK$186.7M (CWA 51% disposal), HK$10.0M (Five Ocean JV disposal), HK$6.5M (JBM share fair-value gain) and HK$1.4M (remeasurement) [S3]. Company-reported adjusted net profit (non-HKFRS): FY2023 HK$114.8M; FY2024 HK$46.4M; discontinued from FY2025 [S3][S1].
Margins (derived)
Revenue CAGR FY2021–FY2025: 5.4% (derived: (1096.6/888.9)^(1/4) − 1). This headline masks two consolidation swings; the underlying Hong Kong distribution book grew only 3.3% in FY2024 and contracted 1.7% in FY2025 [S3][S1].
Commentary. FY2021 was loss-making on inventory write-downs (HK$10.5M) and COVID-era disruption. FY2022 delivered record revenue (HK$1,186.2M) and a 4.9-point gross-margin expansion driven by product-mix optimisation, Mainland "Double 11" e-commerce sales of ~HK$166M and lower write-downs [S4]. FY2023's HK$297.3M profit was overwhelmingly one-off (disposal gains ~HK$203M); underlying operating profit was ~HK$133.7M (derived: reported operating profit less other gains). FY2024 revenue fell 26.9% on CWA deconsolidation, and profit collapsed to HK$6.0M with share-based payments jumping to HK$20.6M [S3]. FY2025's 25.2% revenue rebound was "mainly due to" CWA reconsolidation per management, with gross margin down 2.0 points to 24.6% on unabsorbed procurement-cost increases [S1]. Net profit recovered to HK$15.5M helped by lower share-based payments (HK$6.5M) and a HK$4.4M remeasurement gain.
Interim trend (1H2026 vs 1H2025) [S2]
Two-thirds of the 1H2026 pre-tax profit (HK$4.3M of HK$9.3M) came from a one-off gain on disposal of an undisclosed subsidiary; the remainder reflects G&A savings (staff costs down from HK$43.3M to HK$31.4M) and lower interest [S2].
Balance sheet
Gearing ratio per company definition (net debt / (equity + net debt)) is disclosed only for FY2023–FY2025 in the documents reviewed; FY2021–FY2022 shown as 0 = not disclosed in sources reviewed (derived equivalent: FY2021 39.1%, FY2022 47.7%). FY2025 goodwill HK$203.8M and other intangibles HK$51.5M per S&P breakdown [S7]. At 30 Jun 2026: cash HK$22.3M, bank and other borrowings HK$303.1M, shareholder loans HK$99.9M, lease liabilities HK$7.3M, equity HK$550.0M, gearing 41.7% [S2].
Commentary. The balance sheet has become more levered and less liquid. Cash fell to HK$22.3M at mid-2026 against HK$294.5M of bank debt due within one year [S2]. Shareholder loans doubled in FY2025 (new HK$16.9M loan maturing May 2030; HK$85.0M maturing March 2028) [S1]. Intangibles tripled to HK$255.3M on CWA reconsolidation, creating impairment exposure if Mainland e-commerce underperforms. Prepayments to suppliers (HK$294.3M at FY2025, HK$310.2M at 1H2026) now exceed trade receivables in some periods; management disclosed that only ~26.4% of the 30 Jun 2026 prepayment balance had been utilised by the interim announcement date [S2] — a key quality-of-assets monitorable.
Cash flow [S7]
The company states it did not repurchase its listed securities in FY2024 or FY2025 [S3][S1]; the S&P "repurchase" line most likely reflects share purchases by the share award scheme trustee (consistent with weighted-average shares of 776.2M vs 800M issued in FY2024) — unconfirmed. TTM to 30 Jun 2026: OCF HK$33.8M, FCF HK$33.7M [S7].
Commentary. Free cash flow was negative in three of five years as working capital absorbed HK$470M cumulatively over FY2021–FY2024. FY2025 was the first strongly cash-generative year (FCF HK$96.5M), driven by receivable and inventory releases [S7]. Capex is negligible (asset-light model). Dividends paid in FY2023–FY2024 (HK$80M combined) were funded alongside rising bank borrowings, which roughly doubled during FY2024 [S3].
Ratios (derived unless stated)
FY2023 interest coverage on underlying operating profit (ex ~HK$203M gains) ≈ 5.7x; FY2023 net debt / underlying EBITDA (~HK$156M) ≈ 1.1x. FY2023 working-capital days are distorted by CWA deconsolidation at year-end. S&P's TTM view (to Jun 2026): ROE 5.49%, ROA 2.77%, ROIC 4.84%, current ratio 1.44, debt/equity 0.75, interest coverage 2.64 [S7].
Commentary. Returns on capital have been sub-cost-of-capital since FY2024. The cash conversion cycle lengthened sharply in FY2024 (132 days) as DSO jumped above 110 days and payables were paid down; FY2025 improved but remains above the FY2021–FY2023 range. Receivables aged over 180 days were HK$62.0M at FY2025 (20.8% of gross) and HK$47.1M at 1H2026 [S1][S2].
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment
| Segment (external revenue, HKD Mn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Distribution | 684.3 | 699.6 | 701.6 |
E-commerce | 406.4 | 0 | 243.4 |
Retail store | 108.0 | 176.4 | 151.7 |
Total group revenue | 1,198.6 | 876.0 | 1,096.6 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansRevenue by Segment by Segment Result
| Segment result (HKD Mn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Distribution | 94.9 | 57.3 | 51.1 |
E-commerce | 48.4 | -3.3 | 6.9 |
Retail store | 7.6 | 9.0 | 1.2 |
Total segment results | 150.9 | 62.9 | 59.2 |
Segment Margins & Growth (%) and Revenue by Segment (%)
| Metric (%) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Distribution result margin | 13.9 | 8.2 | 7.3 |
Retail store result margin | 7.0 | 5.1 | 0.8 |
Distribution share of group revenue | 57.1 | 79.9 | 64.0 |
E-commerce share of group revenue | 33.9 | 0.0 | 22.2 |
Retail store share of group revenue | 9.0 | 20.1 | 13.8 |
Revenue by Segment (FY2021–FY2022)
| Segment (legacy basis, external revenue HKD Mn) | FY2021 | FY2022 |
|---|---|---|
E-commerce | 546.0 | 738.7 |
Distribution | 339.7 | 447.5 |
Others (retail) | 3.2 | 0 |
Revenue by Segment — E-commerce
| Segment result (legacy basis, HKD Mn) | FY2021 | FY2022 |
|---|---|---|
E-commerce | 17.7 | 40.7 |
Distribution | -7.8 | 42.2 |
Others | -1.8 | 0 |
Segment Revenue
| Segment | 1H2025 revenue | 1H2026 revenue | YoY | 1H2025 result | 1H2026 result |
|---|---|---|---|---|---|
Distribution | 343.4 | 306.0 | −10.9% | 17.8 | 7.3 |
E-commerce | 87.4 | 127.6 | +45.9% | −3.7 | 13.4 |
Retail stores | 79.2 | 62.5 | −21.2% | 1.0 | −2.6 |
Total | 510.1 | 496.1 | −2.7% | 15.1 | 18.1 |
Group Entities
| Entity | Role | Ownership |
|---|---|---|
Tycoon Empire Investment Limited (BVI) | Immediate and ultimate holding company | Controlling shareholder |
Dynasty Garden Limited | Holding vehicle for CWA | Indirect wholly-owned |
Combo Win Asia Limited and subsidiaries | Mainland e-commerce / distribution | 100% since 28 Feb 2025 |
Hong Ning Hong Limited (HNH) | HK PCM retail / wholesale | 70% since Mar 2024 |
Million Effort Investment Limited | Holding vehicle (HNH stake, Five Ocean) | Wholly-owned |
Key Zone Investment Inc. | Holding vehicle (Jefferine Macau) | Wholly-owned |
Jefferine Macau Limited | Macau distribution | 100% since Apr 2022 |
Fu Qing Chinese Medical Trading Pte. Ltd. | Singapore distribution | Acquired Aug 2021 |
Singapore and Malaysia subsidiaries | SEA distribution (established pre-listing) | Wholly-owned (per disclosure) |
Income Statement and Per-Share Data
| Metric (HKD Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue | 888.9 | 1,186.2 | 1,198.6 | 876.0 | 1,096.6 |
Cost of sales | 737.2 | 924.6 | 877.5 | 643.4 | 826.6 |
Gross profit | 151.7 | 261.5 | 321.1 | 232.7 | 270.0 |
Selling & distribution expenses | 97.2 | 121.4 | 108.5 | 109.9 | 135.3 |
General & administrative expenses | 65.2 | 72.9 | 84.5 | 95.3 | 95.5 |
Other gains/(losses), net | -0.3 | -5.6 | 202.9 | 0.3 | 1.5 |
Operating profit (reported) | -7.8 | 64.9 | 336.6 | 30.0 | 43.5 |
Finance costs | 6.3 | 11.3 | 23.4 | 21.2 | 22.0 |
EBITDA (FY2023–FY2025 company-reported; FY2021–FY2022 derived) | 5.4 | 79.7 | 360.8 | 41.9 | 64.0 |
Profit before tax | -17.5 | 50.4 | 317.7 | 5.5 | 17.5 |
Net profit (incl. NCI) | -17.4 | 43.6 | 297.3 | 6.0 | 15.5 |
Net profit attributable to owners | -18.8 | 43.8 | 297.3 | 3.2 | 15.7 |
EPS basic (HK cents) | -2.0 | 6.0 | 38.0 | 0.4 | 1.9 |
EPS diluted (HK cents) | -2.0 | 6.0 | 38.0 | 0.4 | 1.9 |
Dividend per share (HK cents) | 0 | 3.0 | 7.0 | 0 | 0 |
Margin (%)
| Margin (%) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin | 17.1 | 22.0 | 26.8 | 26.6 | 24.6 |
Operating margin (reported) | -0.9 | 5.5 | 28.1 | 3.4 | 4.0 |
EBITDA margin | 0.6 | 6.7 | 30.1 | 4.8 | 5.8 |
Net margin (incl. NCI) | -2.0 | 3.7 | 24.8 | 0.7 | 1.4 |
Margin Analysis (%) and Per-Share Data
| Metric | 1H2025 | 1H2026 | Change |
|---|---|---|---|
Revenue | 510.1 | 496.1 | −2.7% |
Gross profit | 129.2 | 122.5 | −5.2% |
Gross margin | 25.3% | 24.7% | −0.6pt |
S&D expenses | 71.7 | 70.4 | −1.9% |
G&A expenses | 51.0 | 38.2 | −25.1% |
Other gains, net | 2.9 | 6.0 | incl. HK$4.3M disposal gain |
Finance costs | 12.8 | 10.7 | −16.6% |
Profit/(loss) before tax | −7.4 | 9.3 | turnaround |
Net profit/(loss) | −7.7 | 6.3 | turnaround |
Attributable to owners | −8.0 | 7.1 | turnaround |
EBITDA | 15.9 | 30.9 | +94% |
EPS basic (HK cents) | −1 | 1 | — |
Balance Sheet and Margin Analysis (%)
| Metric (HKD Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets | 881.5 | 1,012.1 | 989.0 | 1,005.6 | 1,170.3 |
Cash & equivalents | 71.6 | 74.6 | 39.1 | 34.0 | 70.3 |
Inventories | 303.2 | 341.8 | 141.3 | 167.0 | 173.9 |
Trade receivables | 205.0 | 256.2 | 236.6 | 270.6 | 296.9 |
Prepayments, deposits & other receivables | 108.3 | 147.7 | 161.3 | 252.5 | 294.3 |
Goodwill & intangibles | 40.1 | 38.7 | 86.2 | 82.9 | 255.3 |
Bank borrowings (all current) | 179.0 | 278.4 | 139.0 | 270.3 | 310.4 |
Shareholder loans | 50.0 | 50.0 | 50.0 | 50.0 | 101.9 |
Lease liabilities | 10.1 | 13.2 | 17.1 | 10.7 | 15.8 |
Total debt incl. leases | 239.1 | 341.6 | 206.2 | 331.0 | 428.1 |
Short-term debt (current) | 235.5 | 338.6 | 197.3 | 326.5 | 408.4 |
Long-term debt (non-current) | 3.6 | 3.0 | 8.9 | 4.5 | 19.6 |
Net debt | 167.5 | 267.0 | 167.1 | 297.0 | 357.7 |
Total equity | 261.3 | 293.2 | 543.5 | 489.0 | 545.2 |
Equity attributable to owners | 257.9 | 293.6 | 536.2 | 478.9 | 537.0 |
Working capital | 77.5 | 114.9 | 233.4 | 264.1 | 238.5 |
Gearing ratio, company definition (%) | 0 | 0 | 23.8 | 38.3 | 40.0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansCash Flow
| Metric (HKD Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow | -36.2 | -52.2 | 11.9 | -76.6 | 97.0 |
Capital expenditure | 7.9 | 1.5 | 3.9 | 2.3 | 0.5 |
Free cash flow | -44.1 | -53.6 | 8.0 | -78.9 | 96.5 |
Dividends paid | 16.0 | 0 | 52.0 | 28.0 | 0 |
Share purchases (per S&P "repurchases") | 0 | 0 | 9.4 | 47.6 | 11.6 |
Change in working capital | -46.4 | -149.6 | -141.8 | -132.4 | 27.2 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE % (attrib. profit / closing owners' equity) | -7.3 | 14.9 | 55.4 | 0.7 | 2.9 |
ROA % (net profit / closing total assets) | -2.0 | 4.3 | 30.1 | 0.6 | 1.3 |
ROIC % (op. profit × (1−16.5%) / (equity + net debt); FY2023 ex-gains) | -1.5 | 9.7 | 15.7 | 3.2 | 4.0 |
Current ratio (x) | 1.13 | 1.16 | 1.54 | 1.52 | 1.40 |
Debt / equity (x, total debt incl. leases) | 0.92 | 1.17 | 0.38 | 0.68 | 0.79 |
Net debt / EBITDA (x) | 31.0 | 3.4 | 0.5 | 7.1 | 5.6 |
Interest coverage (x, op. profit / finance costs) | -1.2 | 5.7 | 14.4 | 1.4 | 2.0 |
Asset turnover (x, revenue / closing assets) | 1.01 | 1.17 | 1.21 | 0.87 | 0.94 |
Days sales outstanding | 84.2 | 78.8 | 72.1 | 112.8 | 98.8 |
Days inventory outstanding | 150.1 | 134.9 | 58.8 | 94.7 | 76.8 |
Days payables outstanding | 151.8 | 119.5 | 65.2 | 75.1 | 64.9 |
Cash conversion cycle (days) | 82.5 | 94.2 | 65.7 | 132.4 | 110.7 |
Revenue by Region
| Region (revenue HKD Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Hong Kong | 225.2 | 321.6 | 623.7 | 709.4 | 680.3 |
Mainland China | 558.8 | 750.9 | 413.9 | 0 | 243.4 |
Macau | 95.8 | 94.6 | 112.7 | 89.3 | 88.0 |
Southeast Asia & others | 9.1 | 19.2 | 48.4 | 77.3 | 85.0 |
Total | 888.9 | 1,186.2 | 1,198.6 | 876.0 | 1,096.6 |
Revenue by Region (FY2023–FY2025)
| Country (revenue HKD Mn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Singapore | 41.8 | 65.6 | 69.6 |
Malaysia | 5.5 | 9.6 | 15.0 |
Others (incl. Thailand) | 1.1 | 2.1 | 0.4 |
Revenue by Region (%)
| Region (YoY growth %) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Hong Kong | 42.8 | 94.0 | 13.7 | -4.1 |
Macau | -1.2 | 19.1 | -20.7 | -1.5 |
Singapore | 111.6 | 121.2 | 56.9 | 6.1 |
Malaysia | 0 | 0 | 74.4 | 57.3 |
Geography Overview
| Geography | Distribution | E-commerce | Retail store | Total |
|---|---|---|---|---|
Hong Kong | 524.2 (+~4.4 reconciling) | — | 151.7 | 680.3 |
Mainland China | — | 243.4 | — | 243.4 |
Macau | 88.0 | — | — | 88.0 |
Singapore / Malaysia / others | 85.0 | — | — | 85.0 |
Total | 701.6 | 243.4 | 151.7 | 1,096.6 |
Geographic Revenue
| Region | 1H2025 | 1H2026 | YoY |
|---|---|---|---|
Hong Kong | 336.6 | 301.2 | −10.5% |
Mainland China | 87.4 | 127.6 | +45.9% |
Macau | 42.9 | 43.7 | +1.8% |
Southeast Asia | 43.2 | 23.6 | −45.4% |
— Singapore | 36.6 | 17.8 | −51.4% |
— Malaysia | 6.3 | 5.7 | −9.4% |
Share Price & Returns
| Reference point | Price (HKD) |
|---|---|
IPO price (Apr 2020) | 1.48 (bottom of range; one aggregator shows 1.49 — discrepancy noted) |
Pre-collapse (mid-Apr 2025, implied by ~HK$2.53bn market cap / 800M shares) | ~3.16 |
29 Apr 2025 close | 0.400 |
31 Jul 2026 | 0.231 |
2 Oct 2026 | 0.249 |
16 Oct 2026 | 0.245 |
Valuation Multiples
| Multiple | Tycoon | Basis |
|---|---|---|
P/E (TTM, attributable profit HK$30.8M) | 7.1x | [S1][S2] |
EV/EBITDA (TTM company EBITDA HK$79.0M) | 7.7x | Derived |
EV/Sales (TTM revenue HK$1,082.6M) | 0.56x | Derived |
P/B (equity attrib. HK$542.6M) | 0.40x | [S2] |
P/TBV | ~0.77x | [S7] |
FCF yield (TTM) | ~15% | [S7] |
Dividend metric
| Dividend metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Interim DPS (HK cents) | 0 | 0 | 3.5 | 0 | 0 |
Final DPS (HK cents) | 0 | 3.0 | 3.5 | 0 | 0 |
Total DPS (HK cents) | 0 | 3.0 | 7.0 | 0 | 0 |
Dividends declared (HKD Mn) | 0 | 24.0 | 56.0 | 0 | 0 |
Debt Maturity Profile
| Maturity bucket (HKD Mn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Within one year | 131.1 | 262.9 | 301.1 |
Second year | 0.5 | 0.5 | 1.4 |
Third to fifth years | 1.5 | 1.6 | 3.1 |
Beyond five years | 6.0 | 5.4 | 4.8 |
Analyst Conclusions
Management guidance
Qualitative only: 2H2026 revenue expected to improve given seasonal peak demand and cost control, with continued profitability; SEA to grow "healthier" on higher-margin mix; Thailand expected to grow; continued expansion into Vietnam, Indonesia and Cambodia with Jacobson's support [S2][S6]. No numeric targets.
Consensus
Not available (no coverage).
Bull case
-
Valuation asymmetry: at ~0.40x book and ~7x trailing earnings with ~15% FCF yield, modest margin recovery could re-rate the equity [S7].
-
Operating leverage from cost cuts: 1H2026 G&A fell 25.1% and finance costs 16.6%; if gross profit stabilises, recurring profit could exceed FY2025 levels [S2].
-
Strategic optionality: Jacobson (17.04%) and JBM linkages create potential for deeper integration or corporate action, while SEA licences provide a platform few HK peers possess [S1].
Bear case
-
Earnings quality: one-off gains drove much of recent profit (HK$4.3M of HK$9.3M 1H2026 PBT); underlying distribution results halved YoY (HK$17.8M to HK$7.3M) [S2].
-
Liquidity squeeze: cash of HK$22.3M against ~HK$295M of bank debt due within a year, floating rates and 2.0x interest cover leave little buffer [S2].
-
Concentration and asset risk: 41.7% customer dependence, HK$310M of supplier prepayments with slow utilisation and HK$204M of goodwill tied to an e-commerce unit that missed targets [S1][S2][S7].
Catalysts and monitorables (next 12 months)
-
FY2026 results (expected by end-March 2027) — 2H2026 revenue rebound and gross-margin trajectory.
-
Bank facility renewals and any new shareholder financing.
-
Utilisation of supplier prepayments and receivable ageing.
-
SEA revenue re-acceleration post-pruning; first Vietnam/Indonesia revenue.
-
Goodwill impairment testing on CWA under the new auditor (Crowe).
-
Further board changes (two NED departures in 14 months) and any change in controlling-shareholder stake or pledges.
-
Customer A relationship and any new exclusive agency wins or losses.
-
Dividend resumption (none since FY2023).
Analyst verdict
Tycoon Group is a sub-scale, founder-controlled consumer-health distributor that has spent three years navigating self-inflicted structural volatility: the 2023 sale of its Mainland e-commerce arm for a large accounting gain, the buyer's failure to pay HK$60M of consideration, and the 2025 forced repurchase that brought the business — and roughly HK$170M of goodwill and intangibles — back onto the balance sheet. Stripped of consolidation effects, the core Hong Kong distribution franchise is flat-to-declining, segment margins have halved since FY2023, and the much-promoted Southeast Asian expansion contracted 45% in 1H2026 as management prioritised margin over scale.
The investment case therefore hinges less on growth than on balance-sheet survival and earnings quality. Positively, FY2025 produced the group's strongest free cash flow in five years (HK$96.5M), management has cut G&A aggressively, and a credible strategic shareholder — Jacobson Pharma — injected equity at a premium after the April 2025 share-price collapse. The shares trade at roughly 0.4x book and 7x trailing earnings, pricing in considerable distress.
Negatively, liquidity is tight (HK$22M cash vs ~HK$295M of bank debt due within a year), asset quality warrants scrutiny (supplier prepayments of HK$310M, slow utilisation, aged receivables), customer concentration is extreme, and governance signals — a combined chair/CEO, a margin-call forced sale, an auditor resignation over fees and a revolving NED seat — argue for a meaningful discount. Profitability remains marginal and partly gain-dependent.
On balance, Tycoon is a high-risk, special-situation micro-cap rather than a quality compounder. Upside requires sustained recurring profit above HK$20M, successful refinancing and evidence that the SEA reset lifts margins. Until FY2026 audited results confirm improved cash conversion and stable bank funding, the.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Tenure / appointment | Other disclosed roles / background |
|---|---|---|---|
Mr. Wong Ka Chun Michael (王嘉俊) | Chairman, Executive Director & CEO | Founder; responsible for strategy since inception | Personally acquired Po Wo Tong brand; controls Tycoon Empire Investment Ltd [S1] |
Mr. Cao Ran (曹冉) | Non-executive Director | Since 1 Jul 2025 | NED of Immunotech Biopharm (6978.HK) since Oct 2025 [S1][S9] |
Ms. Liang Yan (梁艷) | Non-executive Director | On board by Mar 2025 (exact date not confirmed) | — |
Ms. Li Ka Wa Helen (李家華) | Non-executive Director | On board since at least FY2022 | — |
Mr. Lau Ka On David (劉家安) | Non-executive Director | On board since at least FY2022 | — |
Mr. Chung Siu Wah (鍾兆華) | Independent NED | Since at least FY2022 | — |
Ms. Chan Ka Lai Vanessa (陳嘉麗) | Independent NED | Since at least FY2022 | INED of China Renaissance (1911.HK) from Jun 2025; independent director of Hunan Junxin Environmental Protection (301109.SZ) from Aug 2025 [S1] |
Mr. Mak Chung Hong (Mak Tommy Chung Hong) (麥仲康) | Independent NED | Since at least FY2022 | — |
“—” = not publicly disclosed.
Board & Management Changes
| Date | Change |
|---|---|
10 Jan 2025 | Mr. Cao Weiyong resigns as NED; Mr. Hu Yang appointed |
By Mar 2025 | Ms. Chong Yah Lien (NED in FY2022–FY2023) no longer on board; Ms. Liang Yan appears as NED |
1 Jul 2025 | Mr. Hu Yang resigns (work adjustment); Mr. Ng Kwan Ho (ex-JBM Healthcare, Amway HK marketing) and Mr. Cao Ran appointed NEDs |
14 Aug 2026 | Mr. Ng Kwan Ho resigns as NED |
Major Shareholders
| Holder | Stake | Basis / source |
|---|---|---|
Tycoon Empire Investment Ltd (Mr. Wong Ka Chun Michael) | ~35.7% (~319M shares) | Derived: 448.1M shares (56.01%, Oct 2023) [S3] less ~129M force-sold Apr 2025 [S10]; consistent with S&P insider ownership of 35.77% [S7] |
Jacobson Pharma Corporation Ltd group (2633.HK) | 17.04% | Company disclosure, Mar 2026 [S1] |
Free float | ~270M shares (~30%) | S&P estimate [S7] |
Institutional ownership | Not publicly disclosed (S&P shows n/a) | [S7] |
Competitive Landscape
Key Competitors
| Competitor | Segment overlap | Description / positioning | Latest scale (where retrieved) |
|---|---|---|---|
JBM (Healthcare) Ltd (2161.HK) | PCM brands / distribution (also a partner) | Branded healthcare marketer; owns Po Chai Pills, Ho Chai Kung, Tin Hee Tong; acquired ~40 Chinese medicine clinics | FY Mar-2026 revenue HK$834.6M (+6.7%), GP HK$465.5M (55.8%), attributable profit HK$201.1M [S14] |
Jacobson Pharma (2633.HK) | Generics / OTC (also shareholder) | Vertically integrated HK generics maker | FY Mar-2026 revenue HK$1,569.5M (−0.5%), GM 43.2%, attributable profit HK$301.6M [S15] |
DKSH Holding (SIX: DKSH) | Market-expansion services, consumer health distribution in HK/SEA | Global outsourced distribution leader | FY2025 net sales CHF 11.1bn (+2.9% CER); Healthcare CHF 5.8bn [S16] |
Zuellig Pharma | Healthcare distribution (HK/SEA) | Private regional distributor | — |
China Resources Pharmaceutical (3320.HK) | Mainland pharma retail/distribution (pre-IPO investor) | State-backed distributor | — |
Wai Yuen Tong Medicine (0897.HK) | HK PCM brands and retail | PCM manufacturer-retailer | — |
Eu Yan Sang | PCM retail HK/SEA | Private (delisted) | — |
Health & Happiness (1112.HK) | Supplements (Swisse) in HK/Mainland cross-border | Global VMS brand owner | — |
By-health (300146.SZ) | Supplements, Mainland e-commerce | Leading Mainland VMS brand | — |
Watsons / Mannings own-label | Retail-led supplements/personal care | Customers and competitors via private label | — |
“—” = not publicly disclosed.
Peer Comparison FY2025
| Metric | Tycoon (FY2025) | JBM Healthcare (FY Mar-26) | Jacobson Pharma (FY Mar-26) | DKSH (FY2025) |
|---|---|---|---|---|
Revenue | HK$1,096.6M | HK$834.6M | HK$1,569.5M | CHF 11.1bn |
Revenue growth | +25.2% (reported; consolidation-driven) | +6.7% | −0.5% | +2.9% (CER) |
Gross margin | 24.6% | 55.8% | 43.2% | — |
Net margin (attrib.) | 1.4% | 24.1% (derived) | 19.2% | — |
Dividend | Nil | HK17.10 cents total | HK9.00 cents total | — |
Recent Developments
The register extends slightly beyond 18 months to capture the CWA reconsolidation that shapes current reporting.



